Literature DB >> 17440756

Methadone-induced Torsade de pointes after stopping lopinavir-ritonavir.

B Lüthi1, A Huttner, R F Speck, N J Mueller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17440756     DOI： 10.1007/s10096-007-0293-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   5.103


× No keyword cloud information.
  12 in total

1.  Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.

Authors:  Susan Clarke; Fiona Mulcahy; Colm Bergin; Helen Reynolds; Nicola Boyle; Michael Barry; David J Back
Journal:  Clin Infect Dis       Date:  2002-03-19       Impact factor: 9.079

Review 2.  Molecular and clinical determinants of drug-induced long QT syndrome: an iatrogenic channelopathy.

Authors:  Hugues Abriel; Jürg Schläpfer; Dagmar I Keller; Bruno Gavillet; Thierry Buclin; Jérôme Biollaz; Rudolf Stoller; Lukas Kappenberger
Journal:  Swiss Med Wkly       Date:  2004-11-27       Impact factor: 2.193

3.  Dangerous interaction between amiodarone and quinidine.

Authors:  R Tartini; L Kappenberger; W Steinbrunn; U A Meyer
Journal:  Lancet       Date:  1982-06-12       Impact factor: 79.321

4.  Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.

Authors:  Alexander N Katchman; Kelly A McGroary; Michael J Kilborn; Craig A Kornick; Paolo L Manfredi; Raymond L Woosley; Steven N Ebert
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

Review 5.  Methadone-induced Torsade de pointes tachycardias.

Authors:  Christian Sticherling; Beat A Schaer; Peter Ammann; Micha Maeder; Stefan Osswald
Journal:  Swiss Med Wkly       Date:  2005-05-14       Impact factor: 2.193

6.  Torsade de pointes associated with very-high-dose methadone.

Authors:  Mori J Krantz; Laurent Lewkowiez; Helen Hays; Mary Ann Woodroffe; Alastair D Robertson; Philip S Mehler
Journal:  Ann Intern Med       Date:  2002-09-17       Impact factor: 25.391

7.  QT prolongation and Torsades de Pointes in patients infected with human immunodeficiency virus and treated with methadone.

Authors:  Merce Gil; Montserrat Sala; Ignasi Anguera; Olga Chapinal; Manuel Cervantes; Joan R Guma; Ferran Segura
Journal:  Am J Cardiol       Date:  2003-10-15       Impact factor: 2.778

Review 8.  Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors.

Authors:  David Zeltser; Dan Justo; Amir Halkin; Vitaly Prokhorov; Karin Heller; Sami Viskin
Journal:  Medicine (Baltimore)       Date:  2003-07       Impact factor: 1.889

9.  Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.

Authors:  Jun-Sheng Wang; C Lindsay DeVane
Journal:  Drug Metab Dispos       Date:  2003-06       Impact factor: 3.922

10.  The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.

Authors:  Elinore F McCance-Katz; Petrie M Rainey; Gerald Friedland; Peter Jatlow
Journal:  Clin Infect Dis       Date:  2003-08-01       Impact factor: 9.079
View more
  9 in total

Review 1.  Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.

Authors:  Dhananjay Pal; Deep Kwatra; Mukul Minocha; Durga K Paturi; Balasubrahmanyam Budda; Ashim K Mitra
Journal:  Life Sci       Date:  2010-11-01       Impact factor: 5.037

2.  QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel.

Authors:  Judith A Martin; Anthony Campbell; Thomas Killip; Margaret Kotz; Mori J Krantz; Mary Jeanne Kreek; Brian A McCarroll; Davendra Mehta; J Thomas Payte; Barry Stimmel; Trusandra Taylor; Mark C P Haigney; Bonnie B Wilford
Journal:  J Addict Dis       Date:  2011-10

Review 3.  Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.

Authors:  Elinore F McCance-Katz; Lynn E Sullivan; Srikanth Nallani
Journal:  Am J Addict       Date:  2010 Jan-Feb

4.  Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.

Authors:  Jennifer Baker; Petrie M Rainey; David E Moody; Gene D Morse; Qing Ma; Elinore F McCance-Katz
Journal:  Am J Addict       Date:  2010 Jan-Feb

Review 5.  Methadone, buprenorphine, and street drug interactions with antiretroviral medications.

Authors:  Valerie A Gruber; Elinore F McCance-Katz
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

6.  Cytochrome P4503A does not mediate the interaction between methadone and ritonavir-lopinavir.

Authors:  Evan D Kharasch; Kristi Stubbert
Journal:  Drug Metab Dispos       Date:  2013-09-25       Impact factor: 3.922

7.  Methadone, QTc interval prolongation and torsade de pointes: Case reports offer the best understanding of this problem.

Authors:  W Victor R Vieweg; Mehrul Hasnain; Robert H Howland; Thomas Clausen; Jayanthi N Koneru; Christopher Kogut; Ericka L Breden Crouse; Jules C Hancox; Antony Fernandez; Ananda K Pandurangi
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

8.  Moving toward personalized medicine in the methadone maintenance treatment program: a pilot study on the evaluation of treatment responses in Taiwan.

Authors:  Hsin-Ya Lee; Jih-Heng Li; Yuh-Ling Sheu; Hsin-Pei Tang; Wei-Chiao Chang; Tze-Chun Tang; Yi-Chun Yeh; Shing-Yaw Wang; Ray-H Liu
Journal:  Biomed Res Int       Date:  2013-12-16       Impact factor: 3.411

Review 9.  A systematic review of the cardiotoxicity of methadone.

Authors:  Samira Alinejad; Toba Kazemi; Nasim Zamani; Robert S Hoffman; Omid Mehrpour
Journal:  EXCLI J       Date:  2015-05-05       Impact factor: 4.068
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.